Involvement of γ-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex

Yuji Yonezawa, Toshihide Kuroki, Takeshi Kawahara, Nobutada Tashiro, Hideyuki Uchimura

研究成果: ジャーナルへの寄稿記事

109 引用 (Scopus)

抄録

The present study was designed to examine the possible involvement of γ-aminobutyric acid (GABA) neurotransmission in the mechanism of phencyclidine (1-(1-phenylcyclohexyl)piperidine; PCP)-induced dopamine release in the medial prefrontal cortex, using in vivo microdialysis in awake, freely moving rats. Local perfusion via the dialysis probe into the medial prefrontal cortex with PCP (100 and 500 μM) and dizocilpine ((+)-5-methyl-10,11-dihydroxy-5-H-dibenzo(a,d)cyclo-heptan-5,10-imine; MK-801, 10 and 50 μM), a selective non-competitive NMDA receptor antagonist, was found to increase extracellular dopamine levels. Co-perfusion with NMDA (1 mM) or the GABA(A) receptor agonist muscimol (50 μM) attenuated the effects of PCP (500 μM) and MK-801 (50 μM) on extracellular dopamine levels. The dopamine reuptake inhibitor nomifensine (50 μM) also produced an increase in extracellular dopamine levels in the medial prefrontal cortex, but this effect was not affected by co-perfusion with muscimol (50 μM). On the other hand, local perfusion with PCP (100 and 500 μM) and MK-801 (10 and 50 μM), but not nomifensine (50 μM), reduced extracellular GABA levels in the medial prefrontal cortex, Co-perfusion with NMDA (1 mM) reduced the effects of PCP (500 μM) and MK-801 (50 μM) on extracellular GABA levels. These results suggest that PCP may facilitate dopamine release in the medial prefrontal cortex, at least in part, by the inhibition of GABA release via the antagonism of NMDA receptors.

元の言語英語
ページ(範囲)45-56
ページ数12
ジャーナルEuropean Journal of Pharmacology
341
発行部数1
DOI
出版物ステータス出版済み - 1 2 1998

Fingerprint

Aminobutyrates
Phencyclidine
Dizocilpine Maleate
Prefrontal Cortex
Synaptic Transmission
Dopamine
Perfusion
gamma-Aminobutyric Acid
Nomifensine
Muscimol
N-Methylaspartate
N-Methyl-D-Aspartate Receptors
Dopamine Uptake Inhibitors
GABA-A Receptor Agonists
Imines
Microdialysis
Dialysis

All Science Journal Classification (ASJC) codes

  • Pharmacology

これを引用

Involvement of γ-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex. / Yonezawa, Yuji; Kuroki, Toshihide; Kawahara, Takeshi; Tashiro, Nobutada; Uchimura, Hideyuki.

:: European Journal of Pharmacology, 巻 341, 番号 1, 02.01.1998, p. 45-56.

研究成果: ジャーナルへの寄稿記事

Yonezawa, Yuji ; Kuroki, Toshihide ; Kawahara, Takeshi ; Tashiro, Nobutada ; Uchimura, Hideyuki. / Involvement of γ-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex. :: European Journal of Pharmacology. 1998 ; 巻 341, 番号 1. pp. 45-56.
@article{8b58142c8f7b4f22bbb36020d1181aa1,
title = "Involvement of γ-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex",
abstract = "The present study was designed to examine the possible involvement of γ-aminobutyric acid (GABA) neurotransmission in the mechanism of phencyclidine (1-(1-phenylcyclohexyl)piperidine; PCP)-induced dopamine release in the medial prefrontal cortex, using in vivo microdialysis in awake, freely moving rats. Local perfusion via the dialysis probe into the medial prefrontal cortex with PCP (100 and 500 μM) and dizocilpine ((+)-5-methyl-10,11-dihydroxy-5-H-dibenzo(a,d)cyclo-heptan-5,10-imine; MK-801, 10 and 50 μM), a selective non-competitive NMDA receptor antagonist, was found to increase extracellular dopamine levels. Co-perfusion with NMDA (1 mM) or the GABA(A) receptor agonist muscimol (50 μM) attenuated the effects of PCP (500 μM) and MK-801 (50 μM) on extracellular dopamine levels. The dopamine reuptake inhibitor nomifensine (50 μM) also produced an increase in extracellular dopamine levels in the medial prefrontal cortex, but this effect was not affected by co-perfusion with muscimol (50 μM). On the other hand, local perfusion with PCP (100 and 500 μM) and MK-801 (10 and 50 μM), but not nomifensine (50 μM), reduced extracellular GABA levels in the medial prefrontal cortex, Co-perfusion with NMDA (1 mM) reduced the effects of PCP (500 μM) and MK-801 (50 μM) on extracellular GABA levels. These results suggest that PCP may facilitate dopamine release in the medial prefrontal cortex, at least in part, by the inhibition of GABA release via the antagonism of NMDA receptors.",
author = "Yuji Yonezawa and Toshihide Kuroki and Takeshi Kawahara and Nobutada Tashiro and Hideyuki Uchimura",
year = "1998",
month = "1",
day = "2",
doi = "10.1016/S0014-2999(97)01435-0",
language = "English",
volume = "341",
pages = "45--56",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Involvement of γ-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex

AU - Yonezawa, Yuji

AU - Kuroki, Toshihide

AU - Kawahara, Takeshi

AU - Tashiro, Nobutada

AU - Uchimura, Hideyuki

PY - 1998/1/2

Y1 - 1998/1/2

N2 - The present study was designed to examine the possible involvement of γ-aminobutyric acid (GABA) neurotransmission in the mechanism of phencyclidine (1-(1-phenylcyclohexyl)piperidine; PCP)-induced dopamine release in the medial prefrontal cortex, using in vivo microdialysis in awake, freely moving rats. Local perfusion via the dialysis probe into the medial prefrontal cortex with PCP (100 and 500 μM) and dizocilpine ((+)-5-methyl-10,11-dihydroxy-5-H-dibenzo(a,d)cyclo-heptan-5,10-imine; MK-801, 10 and 50 μM), a selective non-competitive NMDA receptor antagonist, was found to increase extracellular dopamine levels. Co-perfusion with NMDA (1 mM) or the GABA(A) receptor agonist muscimol (50 μM) attenuated the effects of PCP (500 μM) and MK-801 (50 μM) on extracellular dopamine levels. The dopamine reuptake inhibitor nomifensine (50 μM) also produced an increase in extracellular dopamine levels in the medial prefrontal cortex, but this effect was not affected by co-perfusion with muscimol (50 μM). On the other hand, local perfusion with PCP (100 and 500 μM) and MK-801 (10 and 50 μM), but not nomifensine (50 μM), reduced extracellular GABA levels in the medial prefrontal cortex, Co-perfusion with NMDA (1 mM) reduced the effects of PCP (500 μM) and MK-801 (50 μM) on extracellular GABA levels. These results suggest that PCP may facilitate dopamine release in the medial prefrontal cortex, at least in part, by the inhibition of GABA release via the antagonism of NMDA receptors.

AB - The present study was designed to examine the possible involvement of γ-aminobutyric acid (GABA) neurotransmission in the mechanism of phencyclidine (1-(1-phenylcyclohexyl)piperidine; PCP)-induced dopamine release in the medial prefrontal cortex, using in vivo microdialysis in awake, freely moving rats. Local perfusion via the dialysis probe into the medial prefrontal cortex with PCP (100 and 500 μM) and dizocilpine ((+)-5-methyl-10,11-dihydroxy-5-H-dibenzo(a,d)cyclo-heptan-5,10-imine; MK-801, 10 and 50 μM), a selective non-competitive NMDA receptor antagonist, was found to increase extracellular dopamine levels. Co-perfusion with NMDA (1 mM) or the GABA(A) receptor agonist muscimol (50 μM) attenuated the effects of PCP (500 μM) and MK-801 (50 μM) on extracellular dopamine levels. The dopamine reuptake inhibitor nomifensine (50 μM) also produced an increase in extracellular dopamine levels in the medial prefrontal cortex, but this effect was not affected by co-perfusion with muscimol (50 μM). On the other hand, local perfusion with PCP (100 and 500 μM) and MK-801 (10 and 50 μM), but not nomifensine (50 μM), reduced extracellular GABA levels in the medial prefrontal cortex, Co-perfusion with NMDA (1 mM) reduced the effects of PCP (500 μM) and MK-801 (50 μM) on extracellular GABA levels. These results suggest that PCP may facilitate dopamine release in the medial prefrontal cortex, at least in part, by the inhibition of GABA release via the antagonism of NMDA receptors.

UR - http://www.scopus.com/inward/record.url?scp=0032472316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032472316&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(97)01435-0

DO - 10.1016/S0014-2999(97)01435-0

M3 - Article

C2 - 9489855

AN - SCOPUS:0032472316

VL - 341

SP - 45

EP - 56

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -